MedPredict, Inc.

One of your key challenges is to stay on top of the latest activities in your target therapeutic categories. What’s happening with competitive compounds in the pipeline? What are their indications and marketing claims likely to be? How are trends in clinical practice evolving, and how will that affect your current and future business?

MedPredict delivers the insights that will drive your strategic decision-making, but without the big price tag and long lead-time required to conduct your own thought leader interviews or market research. We deliver a wide range of syndicated reports that are ready to download today, so you can act on the information right away. And if you don't see what you need in our syndicated reports database, we would be happy to provide you with a customized proposal for proprietary research.

Browse our site to see how MedPredict can provide the thought leader insight you need to make breakthrough strategic decisions.

New Reports Coming Soon...

Cardiovascular -- Acute
Cardiovascular -- Preventive
Diabetes
Obesity
Pain
Respiratory
Cancer -- Post ASCO Reports
Ulcerative Colitis/Crohn's Disease

Upcoming Events...

Coagulation -- Just after ASH2007 we convened a global panel of six thought-leaders (3 US, 2 UK, 1 FR) to discuss coagulation. The Panel covered diseases affecting FVII, FVIII, FIX and von Willebrand factor. The main purpose of the Panel was to probe new developments on extended half-life (EHL) products, new products for inhibitor formation and new competitors to BeneFIX and NovoSeven. For the marketed products the Panelists offered both their perspectives and the positioning messages shared by company representatives. Panelists frame some of these comments within the broader view of each company’s strategy and commitment to the manufacture of blood products.

Psoriasis -- Psoriasis Thought Leader Panel #13 continues our discussion with US and European Thought Leaders. During these conversations the Panelists offered their insight into the following: 1) How to balance long-term toxicities (liver, cardiovascular, infection) against therapeutic benefits. 2) How are differences in the labels affecting Humira and Enbrel use in the US and in Europe? How are these brands being positioned in expectation of ustekinumab’s launch? 3) Is there a need for new anti-TNFs; golimumab, certolizumab, apremilast? 4) What is the product profile and positioning for an oral anti-psoriatic therapy? 5) How to approach combination therapy, and sequenced induction / maintenance. 6) What is the evolving role of methotrexate in the treatment of psoriasis? 7) How do ustekinumab and ABT-874 compare for psoriasis and psoriatic arthritis? How do they compare to anti-TNF therapy? 8) Which is a better research target: IL23 or IL17? 9) New mechanisms.

Multiple Sclerosis -- In this report we continue our discussion with 8 Neurology Thought Leaders (7 North American; 1 European). The Panel begins by addressing the disconnect between the etiology of MS and the current classifications of PPMS, SPMS and RRMS. Choice of therapy will depend on whether the disease has more of an inflammatory or an immunologic component. The discussion leads into use of diagnostics, primary and secondary outcomes, sequencing of induction and maintenance, combinations and treating pediatrics. Balancing safety vs. efficacy, and parenteral vs. oral is challenging in light of the failure of any therapeutic to have a meaningful effect on long-term disability in patients.